olanzapine

P2, N=200, Recruiting, Chinese University of Hong Kong | Not yet recruiting --> Recruiting

P2, N=24, Completed, The University of Technology Sydney | Recruiting --> Completed

P4, N=200, Not yet recruiting, Shanghai 6th People's Hospital

Conversely, compared with those of the model group, the expression of NPY, SOCS3, NLRP3, ASC, cleaved caspase-1, GSDMD-N, and IL-1β was significantly downregulated, and the expression of POMC and LEPR was significantly upregulated in the medium-and high-dose HLWDD groups and the metformin group. These results collectively indicate that HLWDD ameliorates olanzapine-induced feeding dysregulation by mitigating leptin resistance through suppression of NLRP3-driven neuroinflammatory pathways in the arcuate nucleus.

P2, N=200, Not yet recruiting, Chinese University of Hong Kong

P3, N=222, Recruiting, Affiliated Hospital of Qinghai University | Initiation date: Sep 2025 --> Feb 2026

P=N/A, N=238, Not yet recruiting, Henan Cancer Hospital

P4, N=5, Terminated, Ohio State University | N=60 --> 5 | Trial completion date: Jun 2026 --> Jan 2026 | Recruiting --> Terminated; Not able to recruit enough subjects

P3, N=92, Recruiting, The Affiliated People's Hospital of Ningbo University

In summary, our study demonstrated that long-term exposure to olanzapine increases circulating plasma levels of TNF-α, thus leading to increased expression of FABP4 protein in white adipose tissue and subsequently inhibiting Dhhc7expression, which correspondingly leads to reduced membrane translocation of GLUT4 and consequent insulin resistance. In conclusion, this study elucidated the signalling pathway through which olanzapine inhibits GLUT4 membrane transport via the TNF-α/FABP4/Dhhc7 axis, thus ultimately leading to insulin resistance.

P=N/A, N=2000, Recruiting, Shandong Cancer Hospital and Institute

P3, N=360, Recruiting, Alliance for Clinical Trials in Oncology | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Apr 2026 --> Apr 2027